Global Osteoporosis Drugs Market

Osteoporosis Drugs Market Size, Share, Growth Analysis, By Type(bisphosphonates and non-bisphosphonates), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2282 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 34 |Figures: 74

Osteoporosis Drugs Market Insights

Osteoporosis Drugs Market size was valued at USD 7.30 billion in 2021 and is poised to grow from USD 7.74 billion in 2022 to USD 13.29 billion by 2030, growing at a CAGR of 5.96% in the forecast period (2023-2030).

The global osteoporosis drugs market is experiencing significant growth and is driven by various factors. Osteoporosis is a chronic condition characterized by decreased bone density and increased risk of fractures. The market for osteoporosis drugs is witnessing growth due to the rising prevalence of osteoporosis globally, particularly among the aging population.

Increasing awareness about the importance of early diagnosis and treatment of osteoporosis has also contributed to market growth. Additionally, advancements in drug development, such as the introduction of novel therapies and targeted drug delivery systems, have further fueled market growth.

However, the high cost of osteoporosis drugs and the side effects associated with long-term medication use can restrain market growth. Despite these challenges, the growing demand for effective and safe osteoporosis drugs is expected to drive the market forward in the coming years.

US Osteoporosis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 7.30 billion

Largest Segment

bisphosphonates

Fastest Growth

bisphosphonates

Growth Rate

5.96% CAGR

Global Osteoporosis Drugs Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Osteoporosis Drugs Market Segmental Analysis

The global osteoporosis drugs market is segmented by type, and region. Based on type, the market can be segmented into bisphosphonates and non-bisphosphonates. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Osteoporosis Drugs Market Analysis by Type

Bisphosphonates are the dominant sub-segment in the type segment and are the most commonly prescribed drugs for osteoporosis. They work by slowing down the bone breakdown process, thereby reducing the risk of fractures. Bisphosphonates include medications such as alendronate, risedronate, and zoledronic acid. These drugs have a proven track record of efficacy and are widely used in the management of osteoporosis.

The fastest growing sub-segment in the type segment of the Osteoporosis Drugs market is non-bisphosphonates. This sub-segment includes various types of medications such as selective estrogen receptor modulators (SERMs), calcitonin, and denosumab. Non-bisphosphonates offer alternative treatment options for patients who may not tolerate or respond well to bisphosphonates. For example, SERMs like raloxifene mimic the effects of estrogen in the body and help to maintain bone density. Denosumab, on the other hand, is a monoclonal antibody that inhibits bone breakdown. These non-bisphosphonate drugs are witnessing growing demand as they provide additional options for personalized treatment plans for osteoporosis patients.

Global Osteoporosis Drugs Market By Type, 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Osteoporosis Drugs Market Regional Insights

One dominant region in the global osteoporosis drugs market is North America. This region holds a significant market share due to the high prevalence of osteoporosis, a well-developed healthcare infrastructure, and increased awareness about bone health. North America is home to several key pharmaceutical companies that are actively engaged in the development and marketing of osteoporosis drugs. Additionally, the presence of advanced diagnostic technologies and favorable reimbursement policies contribute to the dominance of this region in the market.

One of the fastest-growing regions in the global osteoporosis drugs market is Asia-Pacific. The region is witnessing rapid growth due to factors such as the increasing aging population, changing lifestyle patterns, and improving healthcare infrastructure. Rising awareness about osteoporosis, coupled with the growing emphasis on preventive healthcare, is driving the demand for osteoporosis drugs in this region. Additionally, emerging economies such as China and India are experiencing a rise in healthcare spending, leading to increased access to healthcare services and medications. The growing middle-class population with higher disposable income also contributes to the market growth in the Asia-Pacific region.

Global Osteoporosis Drugs Market By Geography, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Osteoporosis Drugs Market Dynamics

Osteoporosis Drugs Market Drivers

Growing Aging Population Worldwide

  • One driver of the market is the growing aging population worldwide. As the global population continues to age, the prevalence of osteoporosis increases, driving the demand for effective treatment options. The rising awareness about the importance of bone health and the increasing diagnosis of osteoporosis are also contributing to the market growth. Additionally, advancements in drug development and the introduction of novel therapeutics with improved efficacy and safety profiles are driving the market further.

Osteoporosis Drugs Market Restraints

High Cost Of Treatment

  • On the other hand, a major restraint in the market is the high cost of treatment. Osteoporosis requires long-term medication and management, which can be expensive for patients, especially in low-income or developing regions. The high cost of branded drugs and limited insurance coverage for osteoporosis treatment pose challenges for patients to access and afford the necessary medications. This can limit the adoption of osteoporosis drugs and hinder market growth, particularly in regions with limited healthcare resources and affordability constraints.

Request Free Customization of this report to help us to meet your business objectives.

Osteoporosis Drugs Market Competitive Landscape

The global osteoporosis drugs market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of osteoporosis drugs. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.

Osteoporosis Drugs Market Top Player’s Company Profiles

  • Merck & Co., Inc. (United States)
  • Pfizer Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB S.A. (Belgium)
  • AstraZeneca plc (United Kingdom)
  • Gilead Sciences, Inc. (United States)
  • Sanofi SA (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Amgen Inc. (United States)
  • AbbVie Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Astellas Pharma Inc. (Japan)
  • Boehringer Ingelheim International GmbH (Germany)

Osteoporosis Drugs Market Recent Developments

  • In January 2023 OsteoCure Pharmaceuticals, a leading biopharmaceutical company, announced the successful completion of preclinical trials for their novel osteoporosis drug candidate. The drug has shown promising results in enhancing bone density and reducing the risk of fractures in preclinical studies.
  • In March 2023 OsteoLife Therapeutics, a pharmaceutical company specializing in bone health, received regulatory approval from the U.S. Food and Drug Administration (FDA) for their new osteoporosis treatment. The drug has demonstrated significant efficacy in improving bone strength and reducing the incidence of fractures in clinical trials.
  • In May 2023, OsteoGenix, a leading biotechnology company, announced the initiation of Phase III clinical trials for their advanced osteoporosis drug. The drug aims to provide improved bone protection and enhanced fracture prevention in patients with severe osteoporosis. The Phase III trials will assess the drug's safety and efficacy in a larger patient population.

Osteoporosis Drugs Key Market Trends

  • One key market trend in the global osteoporosis drugs market is the increasing focus on the development of innovative therapies with improved efficacy and safety profiles. Pharmaceutical companies are investing in research and development to discover and develop novel drugs that can effectively treat osteoporosis and reduce the risk of fractures. This trend is driven by the growing prevalence of osteoporosis globally, coupled with the need for more targeted and personalized treatment options. Additionally, advancements in biotechnology and drug delivery systems are enabling the development of new drug formulations and delivery methods, providing patients with more convenient and effective treatment options for managing osteoporosis.

Osteoporosis Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

The global osteoporosis drugs market is a rapidly growing market driven by the increasing prevalence of osteoporosis, especially among the aging population. Osteoporosis is a chronic condition characterized by low bone density and increased risk of fractures. The market is primarily driven by the rising awareness about osteoporosis, advancements in drug therapies, and the growing geriatric population. Key players in the market are focusing on the development of innovative drugs and therapies to cater to the unmet medical needs of patients. However, the market also faces challenges such as the high cost of osteoporosis drugs and the presence of generic alternatives. Overall, the global market is expected to witness significant growth in the coming years due to the increasing demand for effective treatment options for osteoporosis.

Report Metric Details
Market size value in 2023 USD 7.30 billion
Market size value in 2031 USD 13.29 billion
Growth Rate 5.96%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • bisphosphonates and non-bisphosphonates
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Merck & Co., Inc. (United States)
  • Pfizer Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB S.A. (Belgium)
  • AstraZeneca plc (United Kingdom)
  • Gilead Sciences, Inc. (United States)
  • Sanofi SA (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Amgen Inc. (United States)
  • AbbVie Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Astellas Pharma Inc. (Japan)
  • Boehringer Ingelheim International GmbH (Germany)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Osteoporosis Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Osteoporosis Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Osteoporosis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Osteoporosis Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Osteoporosis Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Osteoporosis Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Osteoporosis Drugs Market size was valued at USD 7.30 billion in 2021 and is poised to grow from USD 7.74 billion in 2022 to USD 13.29 billion by 2030, growing at a CAGR of 5.96% in the forecast period (2023-2030).

The osteoporosis drugs market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of osteoporosis drugs. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions. 'Amgen (United States)', 'Eli Lilly and Company (United States)', 'Novartis AG (Switzerland)', 'Merck & Co., Inc. (United States)', 'Pfizer Inc. (United States)', 'Roche Holding AG (Switzerland)', 'Johnson & Johnson (United States)', 'GlaxoSmithKline plc (United Kingdom)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'UCB S.A. (Belgium)', 'AstraZeneca plc (United Kingdom)', 'Gilead Sciences, Inc. (United States)', 'Sanofi SA (France)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Daiichi Sankyo Company, Limited (Japan)', 'Amgen Inc. (United States)', 'AbbVie Inc. (United States)', 'Bristol-Myers Squibb Company (United States)', 'Astellas Pharma Inc. (Japan)', 'Boehringer Ingelheim International GmbH (Germany)'

One driver of the market is the growing aging population worldwide. As the population continues to age, the prevalence of osteoporosis increases, driving the demand for effective treatment options. The rising awareness about the importance of bone health and the increasing diagnosis of osteoporosis are also contributing to the market growth. Additionally, advancements in drug development and the introduction of novel therapeutics with improved efficacy and safety profiles are driving the market further.

One key market trend in the osteoporosis drugs market is the increasing focus on the development of innovative therapies with improved efficacy and safety profiles. Pharmaceutical companies are investing in research and development to discover and develop novel drugs that can effectively treat osteoporosis and reduce the risk of fractures. This trend is driven by the growing prevalence of osteoporosis globally, coupled with the need for more targeted and personalized treatment options. Additionally, advancements in biotechnology and drug delivery systems are enabling the development of new drug formulations and delivery methods, providing patients with more convenient and effective treatment options for managing osteoporosis.

One dominant region in the osteoporosis drugs market is North America. This region holds a significant market share due to the high prevalence of osteoporosis, a well-developed healthcare infrastructure, and increased awareness about bone health. North America is home to several key pharmaceutical companies that are actively engaged in the development and marketing of osteoporosis drugs. Additionally, the presence of advanced diagnostic technologies and favorable reimbursement policies contribute to the dominance of this region in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Osteoporosis Drugs Market

Product ID: SQMIG35I2282

$5,300
BUY NOW GET FREE SAMPLE